Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted

BRISTOL MYERS SQUIBB CO

2022-Q2 EPS reported $1.25 revenue$23,535,000,000

Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).
GAAP EPS $0.66 (up 40%); non-GAAP EPS $1.93 (up 18%); GAAP net earnings $1.4B vs $1.1B.
In-line product revenue +11% YoY (Eliquis +16%, Opdivo +8%); Revlimid -22% on generic erosion.
New product portfolio added $257M (Abecma, Opdualag, Reblozyl); Acquired IPRD charges $400M.
2022 GAAP EPS guidance adjusted; non-GAAP EPS guidance reaffirmed; dividend maintained at $0.54/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.